The median age at presentation of patients with acute myeloid leukaemia is 67 years, which means that more than half the cases are in older individuals.¹ For elderly patients who are not enrolled in experimental trials—the preferred option—treatments aimed at changing the natural course of the disease include conventional aggressive chemotherapy and the hypomethylating drugs azacitidine and decitabine. These drugs offer the possibility of achieving a clinical benefit even in the absence of a conventional complete remission, and for some patients, they might also serve as a bridge to allogeneic stem cell transplantation.

中文翻译：

---

瓜地西他滨：急性髓细胞性白血病的新治疗选择？

急性髓细胞性白血病患者的中位年龄为67岁，这意味着一半以上的病例是老年患者。¹对于未参加实验性试验的老年患者（首选方案），旨在改变疾病自然病程的治疗方法包括常规积极化疗以及次甲基化药物阿扎胞苷和地西他滨。这些药物即使在没有常规的完全缓解的情况下也提供了获得临床益处的可能性，并且对于某些患者，它们也可能充当异基因干细胞移植的桥梁。